Helping investors discover, understand, and stay up-to-date on market news and investment opportunities within the Psychedelic industry.

Markets

Performance of psychedelic public companies this past week.

Company News

Psyence Group ($PSYG | $PSYGF) received approval for their Phase IIa clinical trial to assess the efficacy and safety of psilocybin-assisted psychotherapy as a potential treatment for adjustment disorder due to an incurable cancer diagnosis and successfully exported psilocybin mushrooms to Psilo Scientific, a wholly owned subsidiary of Filament Health. Details          

‍Numinus Wellness ($NUMI $NUMIF) announced that their Toronto clinic, the Neurology Centre of Toronto, is now offering ketamine-assisted therapy for patients with neurologic conditions and announced the opening of a new ketamine-assisted therapy clinic in Montreal focused on treating depression, addiction and other common disorders. Details          

Small Pharma ($DMT | $DMTTF) completed enrollment in their Phase IIa clinical trial of DMT-assisted psychotherapy as a potential treatment of Major Depressive Disorder. Press Release          

Biomind Labs ($BMND | $BMNDF) completed dosing administration in their Phase II trial of their novel DMT-based inhaled formulation, BMND01, for treatment-resistant depression. Press Release          

MindMed ($MNMD | $MMED) announced the first patient dosing in their Phase I investigator-initiated study at University Hospital Basel. The study aims to evaluate the effects of MDMA-like substances versus a placebo in healthy volunteers. Press Release          

Optimi Health ($OPTI | $OPTHF) will proceed with a Phase I natural psilocybin and MDMA clinical trial application to Health Canada in partnership with ATMA Journey Centers. ATMA is currently the only Canadian organization to receive approval from Health Canada to conduct a Phase I safety trial with psilocybin in healthy therapists. Press Release          

Algernon Pharmaceuticals ($AGN | $AGNPF) received a cash payment of approximately CDN $450K from their clinical research work in Australia. This brings Algernon''s total cash refund received to date to over CDN $3.0M. Press Release

‍Clearmind Medicine ($CMND | $CMNDF) filed a provisional patent application related to metabolic syndromes including obesity with their proprietary combination of Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc's Palmitoylethanolamide. Press Release          

Media

‍Psychedelic Finance: Interview With Miriam Volat, Director Of The Indigenous Medicine Conservation Fund        

‍Forbes: Colorado Will Vote On Legalizing Psychedelics In November          

Economist: Ketamine, Psilocybin and Ecstasy Are Coming to the Medicine Cabinet          

Harvard Health: The Popularity Of Microdosing Of Psychedelics: What Does The Science Say?            

Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.